Search Results - "Broggini, M."

RAS/RAF/MEK inhibitors in oncology by Rusconi, P, Caiola, E, Broggini, M

“…The RAS/RAF/MEK signaling pathway plays a central role in mediating both proliferation and survival of cancer cells. These proteins are a group of…”
Get more information

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer by Garassino, M.C., Marabese, M., Rusconi, P., Rulli, E., Martelli, O., Farina, G., Scanni, A., Broggini, M.

Get full text

PI3K/AKT/mTOR inhibitors in ovarian cancer by Mazzoletti, M, Broggini, M

“…Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis,…”
Get more information

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial by Rulli, E., Marabese, M., Torri, V., Farina, G., Veronese, S., Bettini, A., Longo, F., Moscetti, L., Ganzinelli, M., Lauricella, C., Copreni, E., Labianca, R., Martelli, O., Marsoni, S., Broggini, M., Garassino, M.C.

“…The prognostic and predictive role of KRAS mutations in advanced nonsmall-cell lung cancer (NSCLC) is still unclear. TAILOR prospectively assessed the…”
Get full text

Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist by Fasolo, A., Sessa, C., Gianni, L., Broggini, M.

“…MET is a tyrosine kinase receptor for hepatocyte growth factor (HGF), primarily expressed on epithelial cells; the activation of MET induces several biological…”
Get full text

Genetic markers for prediction of treatment outcomes in ovarian cancer by Caiola, E, Broggini, M, Marabese, M

“…Drug resistance in epithelial ovarian cancer (EOC) limits the efficacy of therapies for this malignancy. This phenomenon might be partially explained by strong…”
Get full text

Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations by Ganzinelli, M, Mariani, P, Cattaneo, D, Fossati, R, Fruscio, R, Corso, S, Ricci, F, Broggini, M, Damia, G

“…Abstract The purpose of this study was to investigate retrospectively the mRNA expression of genes involved in different DNA repair pathways implicated in…”
Get full text

Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial by Galli, G., Signorelli, D., Vernieri, C., Ganzinelli, M., Moro, M., Fabbri, A., Tamborini, E., Marabese, M., Caiola, E., Broggini, M., Hollander, L., Gallucci, R., Gavazzi, C., Rizzo, A.M., Corsetto, P., Pruneri, G., de Braud, F., Sozzi, G., Torri, V., Garassino, M.C.

Get full text

Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors by Serpico, D., Trama, A., Haspinger, E.R., Agustoni, F., Botta, L., Berardi, R., Palmieri, G., Zucali, P., Gallucci, R., Broggini, M., Gatta, G., Pastorino, U., Pelosi, G., de Braud, F., Garassino, M.C.

“…Molecular aberrations underlying thymic malignancies are poorly understood and lack valid preclinical models. Their rarity and complexity hinders…”
Get full text

731: Studies on the modulation of cisplatin activity in NSCLC by KRAS: Role of specific mutations at codon 12 by Caiola, E, Frapolli, R, Broggini, M, Garassino, M.C, Farina, G

Get full text

A new somatic mutation in the coding region of KRAS gene (G48A) found in a NSCLC patient by Caiola, E, Marabese, M, Garassino, M.C, Rastelli, G, Settanni, G, Brugnara, S, Broggini, M, Ganzinelli, M

Get full text

A novel inhibitor of the PI3K Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate by Falasca, M, Chiozzotto, D, Godage, H Y, Mazzoletti, M, Riley, A M, Previdi, S, Potter, B V L, Broggini, M, Maffucci, T

“…Background: Owing to its role in cancer, the phosphoinositide 3-kinase (PI3K)/Akt pathway is an attractive target for therapeutic intervention. We previously…”
Get full text

HtrA2 enhances the apoptotic functions of p73 on bax by Marabese, M, Mazzoletti, M, Vikhanskaya, F, Broggini, M

“…Regulation of the p73 gene is complex due to the presence of two promoters and the very complex mRNA maturation in both the N-terminal and C-terminal parts of…”
Get full text

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 ( ) autocrine loop in human leukemia cells MOLT-4 by Broggini, M, Marchini, S V, Galliera, E, Borsotti, P, Taraboletti, G, Erba, E, Sironi, M, Jimeno, J, Faircloth, G T, Giavazzi, R, D'Incalci, M

“…The mechanism by which aplidine, a marine natural product in early clinical development as an anticancer agent, induces cell growth inhibition and apoptosis…”
Get full text

922 DRAGO, a P53/p73 Regulated Gene That Modulates Survival in Tumour Prone Mouse Model by Rusconi, P, Polato, F, Musi, A, Broggini, M

Get full text

601: Cisplatin response in a panel of patient-derived ovarian carcinoma xenografts: roles of epithelial mesenchymal transition and DNA repair by Ricci, F, Guffanti, F, Fratelli, M, Perego, P, Fruscio, R, Baldo, R, Magni, S, Broggini, M, Damia, G

Get full text

DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer by Caiola, E, Porcu, L, Fruscio, R, Giuliani, D, Milani, R, Torri, V, Broggini, M, Marabese, M

“…Epithelial ovarian cancer has a poor prognosis owing to late diagnosis and frequent relapse after first-line therapy. Analysis of individual genetic…”
Get full text

Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib by Bianchi, M, Broggini, M, Balzarini, P, Franchi, S, Sacerdote, P

“…This study was designed to investigate the analgesic effects of nimesulide and celecoxib in patients with knee osteoarthritis (OA). In patients with joint…”
Get more information

467 Different KRAS Mutations Confer Different Sensitivity to Cisplatin in Non Small Cell Lung Cancer by Marabese, M, Caiola, E, Rusconi, P, Piva, S, Garassino, M, Farina, G, Broggini, M

Get full text

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy by Ganzinelli, M., Linardou, H., Alvisi, M.F., Caiola, E., Lo Russo, G., Cecere, F.L., Bettini, A.C., Psyrri, A., Milella, M., Rulli, E., Fabbri, A., De Maglie, M., Romanelli, P., Murray, S., Broggini, M., Marabese, M., Garassino, M.C.

“…Platinum-based therapy, combined or not with immune checkpoint inhibitors, represents a front-line choice for patients with non-small-cell lung cancer (NSCLC)…”
Get full text